Project documents | Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067] | Guidance | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Documents

A list of downloadable documents created during development.

Appeal

Appeal
Myeloma UK/Myeloma Society : Appeal letter ^{MSWord 44 KB} 23 September 2024
Sanofi : Appeal letter ^{MSWord 76 KB} 23 September 2024
Myeloma UK/Myeloma Society : Final scrutiny letter ^{MSWord 69 KB} 23 September 2024
Sanofi : Final scrutiny letter ^{MSWord 76 KB} 23 September 2024
Myeloma UK/Myeloma Society : Scrutiny letter ^{MSWord 74 KB} 23 September 2024
Sanofi : Scrutiny letter ^{MSWord 49 KB} 23 September 2024
Appeal decision ^{MSWord 92 KB} 12 November 2024

Final draft guidance

Final draft guidance
Final draft guidance ^{PDF 217 KB} 20 June 2024
Public committee slides ^{PDF 1.08 MB} 20 June 2024
Equality impact assessment (downloadable version) ^{PDF 129 KB} 20 June 2024

Draft guidance

Draft guidance
Appraisal consultation document (PDF version) ^{PDF 257 KB} 09 February 2024
Committee papers ^{PDF 17.83 MB} 09 February 2024
Public committee slides ^{PowerPoint 967 KB} 09 February 2024
Appraisal consultation document (online commenting)
Equality impact assessment (PDF Version) ^{PDF 148 KB} 09 February 2024

Committee meetings

Committee meeting: 1
Supporting documentation Register of interests ^{PDF 172 KB} 09 February 2024
Committee meeting: 2
Topic Register of Interest ^{PDF 159 KB} 20 March 2024

Invitation to participate

Final scope ^{PDF 196 KB} 03 February 2023
Final stakeholder list ^{PDF 167 KB} 03 February 2023
NICE's response to comments on the draft scope and provisional stakeholder list ^{PDF 257 KB} 03 February 2023
Equality impact assessment (Scoping) ^{PDF 125 KB} 03 February 2023